What Are the Top Questions in ALL?

By Chadi Nabhan, MD, MBA, FACP, Elias Jabbour, MD - Last Updated: October 19, 2023

Elias Jabbour, MD, of the University of MD Anderson Cancer Center stops by The HemOnc Pulse for a live show at the Eleventh Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.

In this episode, Dr. Jabbour, who is also an Associate Editor of Blood Cancers Today, the home of The HemOnc Pulse, discusses what he believes are the remaining questions in the treatment of acute lymphoblastic leukemia (ALL). He also discusses the possibility of moving away from chemotherapy for treating ALL and avoiding transplants by using chimeric antigen receptor (CAR)-T therapies.

“[I want to] not only decrease the chemotherapy, but walk away from transplant,” he said. “CAR-T cells can eventually replace autologous transplant.”

Dr. Jabbour acknowledged that in cases of relapse, there were various treatment options available. He stressed the importance of early intervention, stating that it was crucial to act as soon as possible to prevent multiple treatment failures. Some of these options include immunotherapies in the upfront setting and therapies targeting CD22 and CD20 in the second-line setting.

What are the Controversies Surrounding MRD in Blood Cancers?

HMAs Are ‘Cornerstone’ in High-Risk MDS Treatment, Says Jamile Shammo, MD

Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL

Aaron Goodman, MD, Tells Us the 'Crux' of Castleman Disease

Is MRD Negativity the New Benchmark in ALL Treatment Strategies?

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

What Are the Top Questions in ALL?

Related